Benitec Biopharma Ltd (BNTC)

[RCH68]

NSCLC in the article didn't sound all that promising on starting soon.


Tribetarna is a treatment for non-small-cell lung cancer, which is the most common kind of lung cancer and does not respond to normal chemotherapy. The cancer cells contain a gene that produces a protein called class III beta-tubulin (ßIII-tubulin), which protects them from chemotherapy drugs. Tribetarna (tri-beta-RNA) aims to “silence” that gene, preventing it from producing ßIII-tubulin and rendering the cancer susceptible to normal treatment.

The results of the mice tests were promising, if not quite as good as had been hoped. Testing would continue. Science would grind on. If this treatment ever makes it to humans (years hence, or decades), it will improve the outlook for a lot of people with lung cancer, but it won’t be a cure. There are no miracles.